(Shared Conference with Biomarker World Congress and IO Pharma Congress)

Cambridge Healthtech Institute’s 3rd Annual

Quantitative Immune Profiling and Immune Monitoring

Integrated Biomarker Analysis for Precision Immuno-Oncology

June 17, 2019

Advances in immuno-oncology promise to revolutionize cancer treatment. However, many patients do not respond to immunotherapy. Immune profiling promises to identify biomarkers that predict response to immunotherapy and to help monitor its progress. Cambridge Healthtech Institute’s 3rd Annual Quantitative Immune Profiling and Immune Monitoring symposium will cover quantitative approaches to assess the state of the immune system, profile the tumor microenvironment and peripheral blood, determine tumor mutational burden and profile neoepitopes, and develop predictive and response biomarkers.


Molecular Biomarkers of Response to Keytruda

Andrey Loboda, PhD, Director, Genetics and Pharmacogenomics, Merck

Public-Private Partnerships Generating Critical Resources and Novel Methods for Developing Immuno-Oncology Biomarkers

Stacey J. Adam, PhD, Director, Cancer Research Partnerships, Foundation for the National Institutes of Health


The Role of Plasma Exosomes in Monitoring of Immunotherapy Trials

Theresa Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, Hillman Cancer Center, University of Pittsburgh School of Medicine

For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com